Opdivo (nivolumab) is a prescription drug that’s used to treat certain types of cancer. Opdivo can cause side effects that range from mild to serious. Examples include joint pain and rash. The ...

Nivolumab (branded as Opdivo) - will be free from 1 November for eligible people with kidney cancer. Director of pharmaceuticals Geraldine MacGibbon said the drug-funding agency was pleased to ...

Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales. In final guidance ...

Opdivo (nivolumab) is a brand-name drug that’s prescribed for certain types of cancer. Opdivo isn’t known to interact with other medications. Opdivo is prescribed to adults for treating ...

Last week’s NICE rejection of Opdivo for routine use in lung cancer patients has presented BMS with another setback – and an opportunity for Merck Sharp & Dohme (Merck in the US) and its rival ...

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo. Opdivo (nivolumab) with Abraxane (nab-paclitaxel) could expand the therapeutic ...

The best logo maker helps you craft the right branding for your business - even if you've never designed a logo before. Our team of expert reviewers have tested the best free logo makers and the ...

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market ...

Among patients with advanced melanoma, treatment with Opdivo (nivolumab) with or without Yervoy (ipilimumab) benefited both overall survival (OS, the time a patient lives, regardless of disease status ...

Risk of disease recurrence or death was reduced by 42% with Opdivo compared to chemotherapy. 18-month event-free survival was 70% for Opdivo-treated patients, versus 50% for chemotherapy.

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC). These adult patients ...

The story — and the transformative impact — of Bristol Myers Squibb’s Opdivo and Merck’s Keytruda are well known at this point. Yet the field has also been in a moment of commemoration ...